Hsu Y-C, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Reviews Gastroenterol Hepatol 2023;1–14.

Hepatitis B. [https://www.who.int/news-room/fact-sheets/detail/hepatitis-b]

Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chin J Clin Infect Dis. 2023;15(06):401–27.

Google Scholar 

WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. 2021.

Beasley R, Hwang L-Y, Lin C-C, Leu M-L, Stevens C, Szmuness W, Chen K-P. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982;146(2):198–204.

Article  CAS  PubMed  Google Scholar 

Chang K-C, Chang M-H, Chen H-L, Wu J-F, Chang C-H, Hsu H-Y, Ni Y-H. Universal infant hepatitis B virus (HBV) vaccination for 35 years: moving toward the eradication of HBV. J Infect Dis. 2022;225(3):431–5.

Article  CAS  PubMed  Google Scholar 

Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.

Article  CAS  PubMed  Google Scholar 

Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778–809.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.

Article  CAS  PubMed  Google Scholar 

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–8.

Article  CAS  PubMed  Google Scholar 

Broggi A, Granucci F, Zanoni I. Type III interferons: balancing tissue tolerance and resistance to pathogen invasion. J Exp Med 2020, 217(1).

Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005;22(6):519–28.

Article  CAS  PubMed  Google Scholar 

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. A ASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.

Article  PubMed  Google Scholar 

Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.

Article  Google Scholar 

Hsu C-W, Su W-W, Lee C-M, Peng C-Y, Chuang W-L, Kao J-H, Chu H-C, Huang Y-H, Chien R-N, Liaw Y-F. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117(7):588–97.

Article  CAS  PubMed  Google Scholar 

Lin Jinxiang YK. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B. J Practical Hepatol. 2021;24(1):27–30.

Google Scholar 

Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993;119(4):312–23.

Article  CAS  PubMed  Google Scholar 

Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology. 2011;140(7):2074–83. e2072.

Article  PubMed  Google Scholar 

Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B virus does not interfere with innate immune responses in the human liver. Gastroenterology. 2018;154(6):1778–90.

Article  CAS  PubMed  Google Scholar 

Liaw YF, Jia JD, Chan HLY, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54(5):1591–9.

Article  CAS  PubMed  Google Scholar 

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.

Article  CAS  PubMed  Google Scholar 

İnan N, Tabak F. Hepatitis B Virus: Biology and Life Cycle. Viral Hepatit Dergisi. 2015;21(1):1–7.

Article  Google Scholar 

Tsai K, Cullen BR. Epigenetic and epitranscriptomic regulation of viral replication. Nat Rev Microbiol. 2020;18(10):559–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.

Hu J. Hepatitis B virus virology and replication. Hepatitis B virus in human diseases. Springer; 2016. pp. 1–34.

Summers J, O’Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci. 1975;72(11):4597–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Seeger C. Hepadnavirus Genome Replication and Persistence. Cold Spring Harbor Perspect Med 2015, 5(7).

Li W, Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: basic insights and clinical implications. J Hepatol. 2016;64(1):S32–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.

Article  PubMed  PubMed Central  Google Scholar 

Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun J-H. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci. 2019;116(17):8487–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu H, Ren J, Deng H, Li L, Zhang Z, Cheng S, Guo Z, Huang A, Dang Y, Song K. Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus. J Hepatol 2024.

Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11(4):685–706. vil.

Article  PubMed  PubMed Central  Google Scholar 

Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A. Phosphorylation-dependent binding of Hepatitis B Virus Core particles to the Nuclear Pore Complex. J Cell Biol. 1999;145(1):45–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ezzikouri S, Ozawa M, Kohara M, Elmdaghri N, Benjelloun S, Tsukiyama-Kohara K. Recent insights into hepatitis B virus-host interactions. J Med Virol. 2014;86(6):925–32.

Article  PubMed  Google Scholar 

Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84.

Article  CAS  PubMed  Google Scholar 

Koniger C, Wingert I, Marsmann M, Rosler C, Beck J, Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014;111(40):E4244–4253.

Article  PubMed  PubMed Central  Google Scholar 

Bartenschlager R, Cosset FL, Lohmann V. Hepatitis C virus replication cycle. J Hepatol. 2010;53(3):583–5.

Article  PubMed  Google Scholar 

Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 2017;11(6):500–8.

Article  CAS  PubMed  Google Scholar 

Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun. 2021;12(1):1591.